Company ProfilePremium

Agro Phos (India) Limited

Company Profile Analysis

Ticker: AGROPHOS.NS

ESOMAR 23 Corporate BadgeISO Certifications Badge
Agro Phos (India) Limited - Company showcase

Year Founded & Workforce

2001

154 Employees

Agro Phos (India) Limited logo

Agro Phos (India) Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Agro Phos (India) Limited Overview

Agro Phos (India) Limited is an Indore-based, promoter-controlled micro-cap manufacturer of Single Super Phosphate (SSP), the simplest and cheapest phosphatic fertiliser in India's Nutrient-Based Subsidy (NBS) system. With two plants in Madhya Pradesh — Dewas (45,000 MTPA) and Meghnagar, Jhabua district (115,000 MTPA), for a combined 160,000 MTPA — it is a small, regional, single-product player in a fragmented SSP industry dominated by larger integrated producers such as Khaitan Chemicals & Fertilizers, Rama Phosphates, Madhya Bharat Agro Products and Coromandel International. SSP accounted for roughly 85–90% of sales over FY2023–FY2025 and about 99% in 9MFY2026. The company sells through its own network of 200+ dealers across six states and, increasingly, through bulk off-take memoranda with public-sector and national marketers (Indian Potash, HURL, RCF, Matix, MAIDC, BVFCL). Its economics are dictated by government subsidy rates, imported rock-phosphate costs, monsoon quality and working-capital intensity rather than by brand or technology.


What the company does

Agro Phos manufactures phosphatic and allied fertilisers and trades complementary fertilisers. Its manufactured portfolio, as described in exchange filings and CARE Ratings' rationale, consists of Single Super Phosphate (SSP), Nitrogen-Phosphorus-Potassium (NPK) mixtures, Zinc Sulphate, Phosphate Rich Organic Manure (PROM), Potash Derived from Molasses (PDM), organic manure, and Calcium Sulphate (sold as soil conditioner / gypsum). It also trades Di-Ammonium Phosphate (DAP), Urea, Ammonium Sulphate and other fertilisers opportunistically, depending on customer demand and market conditions. Historically the company also reported a minor "Others" activity (commodity trading), but in its latest quarterly integrated filings (Q2 FY2026) it declares a single reportable segment: Fertilisers.

Company's own description (paraphrased from annual report and filings)

The company describes itself as an ISO 9001:2008-certified fertiliser manufacturer whose Dewas and Meghnagar facilities are equipped with machinery, cranes, conveyor belts and handling equipment for smooth processing and logistics, with a fully integrated process running from raw-material procurement through final testing and bagging for direct farmer use. It packs product in "gazette" bags it describes as easy to handle and stack, and it operates an in-house testing laboratory to check product against quality standards under the Fertiliser (Control) Order, 1985.

Business model and revenue model

Revenue streamNatureApprox. shareSource / basis
Manufactured fertiliser sales (SSP dominant, plus NPK, ZnSO4, PROM, PDM, gypsum)Product sale; realisation = farm-gate MRP net of trade margins + government NBS subsidy on SSP/NPK credited to manufacturer after point-of-sale verification~91% of net sales FY2025 (~90% FY2024)CARE Ratings, 31-Mar-2026
Traded fertilisers (DAP, Urea, Ammonium Sulphate, others)Merchant trading, low margin~9% FY2025 (~10% FY2024)CARE Ratings, 31-Mar-2026
Services / subscription / licensing—0%—

The revenue model is purely product-based. A material portion of each tonne's realisation is the government subsidy, which is paid with a lag; this is why the company's receivables, working-capital borrowings and liquidity swing with subsidy-release timing. CARE notes that FY2025 sales growth was driven by higher subsidy rates and volumes (manufacturing volumes +~5%, realisations +~6%).

Value-chain position

Agro Phos sits in the conversion stage of the phosphate chain: it buys imported rock phosphate (mainly from Egypt and Jordan, per CARE) and locally sourced sulphuric acid, acidulates the rock to produce SSP (≈16% P2O5 water-soluble plus sulphur and calcium), then bags and distributes. It is not backward-integrated into sulphuric acid or phosphoric acid (unlike larger peers such as Khaitan, Rama and Madhya Bharat Agro, which own acid plants), and it has no captive rock source. Historically, the Government of India told Parliament that Rajasthan State Mines and Minerals Ltd (RSMML) was the company's indigenous rock-phosphate source; current sourcing is predominantly import-based per CARE.

Customer types and end-markets

Customer typeDescription
Dealers / distributors / retailers200+ dealers across Maharashtra, Madhya Pradesh, Rajasthan, Uttar Pradesh, Chhattisgarh and Andhra Pradesh (CARE, Mar-2026)
Institutional marketers (bulk off-take)Indian Potash Ltd (IPL), Hindustan Urvarak & Rasayan Ltd (HURL), Rashtriya Chemicals & Fertilizers (RCF), Matix Fertilisers & Chemicals, Maharashtra Agro Industries Development Corporation (MAIDC), Brahmaputra Valley Fertilizer Corporation (BVFCL)
Government (indirect)Department of Fertilizers pays NBS subsidy; state governments license manufacturing and enforce quality
End usersIndian farmers — particularly oilseed (soybean, mustard, groundnut), pulse and cereal growers in central India, where SSP's sulphur content is valued

Independent characterisation

Agro Phos is best understood as a subsidy-dependent, working-capital-heavy, single-product commodity converter of sub-scale size (revenue ≈ INR 148 Cr in FY2026, roughly one-sixth of Rama Phosphates and one-thirteenth of Madhya Bharat Agro). Its competitive edge is local: proximity to central-Indian SSP demand, a long-standing promoter presence, and the ability to run plants for institutional marketers who need SSP volume without building capacity. Its structural weaknesses — no acid integration, no captive raw material, almost full utilisation of bank working-capital lines, and earnings that swing between losses (FY2024) and modest profits — mean its returns on capital are cyclical and low on a multi-year average (3-year average ROE ≈ 3% per Screener.in). Strategically, the company has tilted from dealer-led branded retail toward contract manufacturing/off-take for national marketers, which raises volume visibility but caps pricing power.

Strategy

Stated strategy (themes)

The company does not publish investor presentations, hold earnings calls or issue medium-term guidance. Strategic themes are inferred from Directors' Reports, Regulation 30 disclosures and CARE's discussions with management:

  1. Volume assurance through institutional off-take — repeated MoUs with public-sector and national marketers (IPL, HURL, RCF, MAIDC, BVFCL, Matix) to keep 160,000 MTPA of capacity loaded.

  2. SSP-centric portfolio with value-added variants — "Krishi Samridhi" variant SSP, PROM, PDM and gypsum to broaden the basket around the core SSP line.

  3. Inorganic expansion attempts — the 2025 Bharat Phosphates & Chemicals acquisition (withdrawn) and the earlier Shri Tulsi Phosphate investment (now largely exited).

  4. Capital discipline / shareholder return — first meaningful dividend (INR 1.00) paid for FY2025.

  5. Circular raw materials — PDM made from distillery spent-wash ash (Som Distilleries MoU).

Initiatives in the last 24 months (Oct 2024 – Oct 2026)

DateInitiativeTypeStatus / outcome
28 May 2024 (context)HURL MoU for 125,350 MT SSPOff-take partnershipTerm ended 27 May 2025; renewal not disclosed
16 Jul 2025Acquisition of Bharat Phosphates & Chemicals Pvt. Ltd. business undertaking (≤ INR 3 Cr) as WOSM&AWithdrawn 29 May 2026
06 Sep 2025INR 1.00/share final dividend for FY2025Capital returnPaid c. 30 Oct 2025
31 Dec 2025Sale of 520,000 Shri Tulsi Phosphate shares to promoterPortfolio rationalisationCompleted; associate status ended
17 Mar 2026RCF marketing & distribution MoU for SSP (to 01 Jun 2027)Channel partnershipActive
31 Mar 2026Bank facilities restructured: one bank's limits withdrawn on no-dues; new INR 12 Cr LT/ST facility ratedFinancingCompleted
08 Sep 2026Acuité rating BBB-/A3 on enhanced INR 51.75 Cr facilitiesFinancingCompleted (possibly to support larger working-capital lines)
2,026Board refresh: new ID (Sakina Dharwala), committee reconstitutionGovernanceCompleted

ESG / sustainability commitments, cost programmes, guidance

ItemStatus
Emissions or net-zero targets—
Cost-reduction programmes with targets—
Medium-term financial targets / guidanceNone issued
Capacity expansion plansNone announced (contrast: Rama, Madhya Bharat and Khaitan all have announced SSP/acid expansions)

CARE's rating sensitivities provide the only quasi-targets: an upgrade would need sustained total operating income above INR 130 Cr with PBILDT margin of 8%, gearing below 0.5x, interest coverage above 5x and total debt/GCA below 5x. FY2026 met the revenue and margin thresholds but not the coverage threshold (≈4.2x).

Products & Services

All products sit in the single Fertilisers segment. Pricing for subsidised products (SSP, NPK) follows MRP plus NBS subsidy; product-level prices are not disclosed by the company.

Manufactured products

ProductDescription & specificationsTarget customerLaunch / latest yearPricing modelFlagship brand(s)
Single Super Phosphate (SSP)Phosphatic fertiliser made by acidulating rock phosphate with sulphuric acid; delivers water-soluble P2O5 (~16% standard grade) plus sulphur and calcium. Produced at both Dewas and Meghnagar (combined 160,000 MTPA). Variants are made for institutional marketersFarmers via dealers; bulk off-take by IPL, HURL, RCF, Matix, MAIDC, BVFCLSince inception (exact year not disclosed)MRP + NBS subsidy (government-notified per-tonne rate)"Smriddhi" (company's SSP brand per Musaffa/company data); "Krishi Samridhi" (variant marketed by Matix in West Bengal and MAIDC in Maharashtra)
NPK mixturesNitrogen-phosphorus-potassium compound/mixed fertilisersFarmers; IPL marketing arrangement for 25,000 MTPA in MP and Chhattisgarh—MRP + NBS subsidy (where notified)—
Zinc SulphateMicronutrient fertiliser to correct zinc deficiencyFarmers (paddy, wheat, maize belts)—Market-priced (non-subsidised)—
Phosphate Rich Organic Manure (PROM)Organic manure enriched with rock phosphate; FCO-notifiedOrganic/low-cost input buyers—Market-priced; Market Development Assistance eligibility not disclosed—
Potash Derived from Molasses (PDM)Potassic fertiliser (K2O 14.5%) made from distillery spent-wash ash; raw material supplied under MoU with Som Distilleries; company described as the leading MP producer at launchFarmers seeking cheaper potash substitutec. 2019 (licence from MP Farmer Welfare & Agriculture Development Dept.)NBS-eligible (PDM is in the NBS list)—
Organic manureGeneral organic manureFarmers—Market-priced—
Calcium Sulphate (soil conditioner / gypsum)Soil amendment for sodic soils and sulphur/calcium supply; by-product synergy with SSPFarmers—Market-priced—

Traded products

ProductDescriptionBasis
Di-Ammonium Phosphate (DAP)Traded opportunistically per customer demandCompany profile; CARE
UreaTraded opportunisticallyCompany profile; CARE
Ammonium SulphateTraded opportunisticallyCompany profile; CARE
Other fertilisers / commoditiesHistorically commodity trading ("Others")Older segment descriptions

Services

None. The in-house testing laboratory is a quality-control facility, not a commercial service.

Institutional supply/marketing agreements (portfolio channels)

CounterpartyProductVolumeTermGeography
Indian Potash LtdSSPMinimum 40,000 MTPA ±10%Long-standing (dates not disclosed)MP, Chhattisgarh, Maharashtra
Indian Potash LtdNPK25,000 MTPALong-standingMP, Chhattisgarh
Matix Fertilisers & ChemicalsSSP variant ("Krishi Samridhi")Minimum 60,000 MTPARolling; latest disclosed 17 Apr 2024 – 31 Mar 2025West Bengal
HURLSSP125,350 MT28 May 2024 – 27 May 2025—
RCFSSP—17 Mar 2026 – 01 Jun 2027RCF network
MAIDCSSP ("Krishi Samridhi")25,227 tFrom 01 Mar 2023Maharashtra
BVFCLSSP25,000 tFrom 12 Jan 2023North-East (BVFCL network)

Financial Narrative

Basis: Standalone, INR Cr, FY ending 31 March. FY2022–FY2025 from CMOTS standalone P&L (Arihant Capital) and CARE; FY2026 from the four quarterly standalone results filed on NSE (summed, via Screener.in) cross-checked with Anand Rathi. Gross profit is computed as net sales minus raw materials consumed adjusted for inventory change (CMOTS line items); it is not a company-reported line.

Income statement

Notes: FY2024 EPS per Screener standalone (–3.77); TipRanks consolidated shows –2.60. FY2026 DPS: no dividend for FY2026 appears in exchange data reviewed (Screener shows 0% payout and 0% yield); not confirmed by the annual report text — treat as "no dividend declared, unconfirmed". FY2026 tax derived as PBT less PAT.

Margins and growth

Commentary. Revenue nearly doubled in FY2022 (INR 59.98 Cr → 116.06 Cr) as global phosphate prices spiked and the government raised NBS rates, inflating SSP realisations. FY2023 extended the high-price year to a revenue peak of INR 131 Cr. FY2024 was the inflection downward: the subsidy budget was cut as raw-material prices eased, rainfall was deficient in key markets (the FY2024 Directors' Report attributes lower results to reduced subsidy allocation and inadequate rainfall), and the company was left with high-cost inventory against falling realisations, producing a standalone operating loss of about INR 6 Cr and a net loss of INR 7.65 Cr — including two consecutive loss quarters (Dec-2023, Mar-2024). FY2025 brought recovery, driven per CARE by higher subsidy rates and ~5% higher manufacturing volume, with EBITDA margin rebounding to 11.7%. FY2026 delivered record revenue of INR 147.95 Cr (+23%) on the back of Kharif 2025 subsidy increases for SSP (industry sources cite an SSP NBS rate of about INR 7,263/MT for Kharif 2025) and DAP shortages that shifted farmers toward SSP. However, the year was front-loaded: standalone EBITDA margin was 19.9% in Q1 FY2026 but fell steadily to 9.5%, 7.8% and 6.1% in Q2–Q4, and Q1 FY2027 revenue fell 27% YoY to INR 28.92 Cr with PAT down 69% to INR 1.32 Cr. Finance costs have more than doubled since FY2022 (1.67 → 3.95 Cr), reflecting higher working-capital borrowing.

Quarterly trajectory (standalone, INR Cr)

Source: Screener.in, compiled from NSE quarterly standalone filings. Consolidated Q4 FY2026 showed a net loss of about INR 0.29 Cr (Kotak Neo), versus standalone profit of INR 1.02 Cr.

Balance sheet (standalone, INR Cr; Screener figures rounded to whole crore)

Notes: (a) Cash FY2025 is CARE's "free cash and bank balance" (INR 0.10 Cr); FY2026 cash INR 22.31 million from StockAnalysis. (b) Debt split: CARE describes facilities as fund-based cash credit (INR 17.75 Cr LT-rated CC), LT/ST fund/non-fund (INR 12 Cr) and LC (INR 16 Cr), with scheduled term-debt repayment of only INR 0.23 Cr in FY2026 — i.e., borrowings are overwhelmingly working-capital; precise ST/LT split not disclosed. (c) Reserves rising in FY2024 despite a net loss is anomalous in the aggregated data and could reflect OCI/revaluation or data rounding; not verifiable from sources reviewed. (d) CARE's overall gearing (0.54x FY2024; 0.65x FY2025) implies a broader debt definition (likely including LC-backed acceptances) and/or adjusted net worth versus Screener's ~0.44x. (e) No goodwill or intangibles disclosed. (f) Book value per share INR 34.8 (Screener, Oct 2026).

Cash flow (standalone, INR Cr)

Dividends paid derived as DPS × 20.27 million shares (FY2022 interim INR 0.25; FY2026 cash outflow for FY2025 final INR 1.00 paid c. 30 Oct 2025). No buyback has ever been announced.

Ratios

Sources: Screener.in (ROCE, D/E inputs, day-counts); CARE (gearing, coverage); current ratio from StockAnalysis (latest). ROIC is not publicly disclosed. CARE separately measured the operating cycle at 135 days (FY2025) vs 132 days (FY2024) and total debt / gross cash accruals at 4.48x for FY2025, with GCA of INR 9.32 Cr (FY2025) versus a cash loss of INR 8.77 Cr (FY2024).

Ratio commentary. Returns are adequate in good years (ROE 12–13%) but negative in bad ones, giving a weak through-cycle average (Screener: 3-year ROE ≈ 3%, 5-year ≈ 6%). The single most important balance-sheet dynamic is inventory: inventory days swung from 145 (FY2022) to 291 (FY2025) as the company stocked imported rock phosphate and finished SSP ahead of seasons, funded partly by supplier credit (payable days 227 in FY2025) and partly by bank lines that CARE describes as almost fully utilised over the 12 months to February 2026. FY2026 improved the cash cycle to 93 days. Leverage is moderate in absolute terms (net debt ≈ 1.7x EBITDA), but liquidity is thin: CARE characterises liquidity as "stretched", with negligible free cash and near-full use of working-capital limits.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Income Statement and Per-Share Data

Metric (INR Cr)FY2022FY2023FY2024FY2025FY2026

Revenue / net sales

116.06131.02103.82119.88147.95

Raw materials consumed adj. for stock change

79.5389.4380.7475.18—

Gross profit (derived)

36.5341.5923.0844.70—

EBITDA excl. other income

8.7910.46-5.9913.9716.46

Other income

1.190.340.630.911.22

Depreciation

1.231.561.731.951.96

Operating income (EBIT excl. OI)

7.568.90-7.7212.0214.50

Interest / finance cost

1.672.133.413.833.95

Pre-tax income

7.087.11-10.509.1011.77

Tax (current + deferred)

1.242.10-2.853.843.60

Net income

5.835.00-7.655.268.17

EPS basic (INR)

2.882.47-3.772.594.03

EPS diluted (INR)

2.882.47-3.772.594.03

Dividend per share declared for year (INR)

0.25001.000

Margin Analysis (%)

Metric (%)FY2022FY2023FY2024FY2025FY2026

Gross margin (derived)

31.531.722.237.3—

EBITDA margin (excl. OI)

7.68.0-5.811.711.1

Operating (EBIT) margin

6.56.8-7.410.09.8

Pre-tax margin

6.15.4-10.17.68.0

Net margin

5.03.8-7.44.45.5

Revenue growth YoY

93.512.9-20.815.523.4

CAGR metric

Value

Basis

———

Revenue CAGR FY2022–FY2026 (4 yrs)

≈ 6.3%

116.06 → 147.95

———

Revenue CAGR FY2021–FY2026 (5 yrs)

≈ 19.8%

59.98 → 147.95 (Screener reports 20%)

———

10-year sales CAGR

7%

Screener.in

———

5-year profit CAGR

20%

Screener.in

———

Income Statement and Margin Analysis (%)

Metric (INR Cr)Q1FY25Q2FY25Q3FY25Q4FY25Q1FY26Q2FY26Q3FY26Q4FY26Q1FY27

Sales

23.9231.5022.8130.1139.8040.0835.8432.2328.92

Operating profit

-1.803.174.183.907.933.792.791.953.16

OPM (%)

-7.510.118.313.019.99.57.86.110.9

PBT

0.053.602.792.656.392.371.481.531.80

Net profit

-0.190.442.492.514.292.010.851.021.32

EPS (INR)

-0.090.221.231.242.120.990.420.500.65

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Balance Sheet

Metric (INR Cr)FY2022FY2023FY2024FY2025FY2026

Total assets

85130109157154

Net fixed assets

2122242321

Capital work-in-progress

13000

Investments

10555

Other assets (inventory, receivables incl. subsidy, cash)

6210580129127

Cash & equivalents

———0.102.23

Total debt

1327292830

Net debt (approx.)

———2828

Equity share capital

2020202020

Reserves

2732394450

Total equity

4752596470

Goodwill & intangibles

00000

Other liabilities (payables, provisions)

2551216453

Working capital proxy (other assets – other liabilities)

3754596574

Cash Flow

Metric (INR Cr)FY2022FY2023FY2024FY2025FY2026

Operating cash flow (Screener)

14-6334

Operating cash flow (CARE, where disclosed)

——-11.49-3.29—

Capital expenditure (derived = CFO – FCF)

75201

Free cash flow (Screener)

7-11133

Investing cash flow

-10-7-20-1

Financing cash flow

-312-1-4-3

Dividends paid (approx.)

0.510002.03

Share buybacks

00000

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2022FY2023FY2024FY2025FY2026

ROE (%, PAT / avg equity)

13.210.1-13.88.612.2

ROA (%, PAT / avg assets)

7.44.7-6.44.05.3

ROCE (%, Screener)

1413-91416

Current ratio (x)

————1.58

Debt / equity (x, Screener basis)

0.280.520.490.440.43

Overall gearing (x, CARE basis)

——0.540.65—

Net debt / EBITDA (x)

1.52.6—2.01.7

Interest coverage (x, EBITDA / interest)

5.34.9-1.83.64.2

Interest coverage (x, CARE PBILDT basis)

———3.65—

Asset turnover (x, sales / avg assets)

1.471.220.870.900.95

Debtor days

3645446865

Inventory days

145250154291177

Payable days

8418374227148

Cash conversion cycle (days)

9711312413293

Working-capital days

7578105116109

Revenue by Region and Region Margins & Growth (%)

Region (INR Cr)FY2024FY2025FY2026

India (domestic)

103.82119.88147.95

Outside India

000

India YoY growth (%)

-20.815.523.4

State Details

StateChannel presenceNotes

Madhya Pradesh

Own dealers; IPL (SSP and NPK)

Home state; both plants located here

Maharashtra

Own dealers; IPL (SSP); MAIDC (Krishi Samridhi)

Large soybean/cotton SSP market

Chhattisgarh

Own dealers; IPL (SSP and NPK)

Also home of former associate Shri Tulsi Phosphate

Rajasthan

Own dealers

Mustard/groundnut SSP market

Uttar Pradesh

Own dealers

—

Andhra Pradesh

Own dealers

—

West Bengal

Matix (Krishi Samridhi variant)

Contract supply

North-East

BVFCL MoU (2023)

Contract supply

Capital Markets

MeasureValueSource

Last close

INR 22.9 (09 Oct 2026)

Screener.in

52-week high / low

INR 44.4 / 21.0

Screener.in

1-year return

≈ -45%

Screener.in

3-year price CAGR

≈ -16% p.a.

Screener.in

5-year price CAGR

≈ +4% p.a.

Screener.in

IPO price (2016)

INR 22

NSE/PTI

Listing-day close (16 Nov 2016)

INR 22.85

PTI

Liquidity

Thinly traded (vendor estimates ~INR 5–6 lakh/day)

VestAI

Valuation Multiples

MultipleAgro PhosBasis

P/E (TTM standalone, PAT ≈ INR 5.20 Cr)

9.2x

Screener.in

P/E (FY2026 standalone PAT INR 8.17 Cr)

5.7x

Derived

P/B

0.66x

Screener (BV INR 34.8)

EV (mkt cap 46.4 + net debt ≈ 27.6)

≈ INR 74 Cr

Derived

EV / EBITDA (TTM EBITDA ≈ INR 11.7 Cr)

≈ 6.3x

Derived

EV / Sales (TTM sales ≈ INR 137 Cr)

≈ 0.54x

Derived

Dividend yield (trailing)

0% on Screener (FY2026 no dividend); ~4.4% on the INR 1.00 paid Oct 2025 at current price

Screener / derived

Peer multiple (approx., dates vary)

P/E (x)

Source

Khaitan Chemicals & Fertilizers

7.6

Screener.in (2026)

Rama Phosphates

≈ 8.3 (mkt cap ≈ INR 439 Cr / FY2026 PAT INR 52.7 Cr)

Fyers / derived

Dividend metric (INR per share)

Dividend metric (INR per share)FY2022FY2023FY2024FY2025FY2026

Dividend declared for the year

0.25001.000

Payout ratio (% of standalone EPS)

8.70038.60

Ex-date

Type

Amount (INR)

———

24 Sep 2018

Final (FY2018)

0.05———

16 Mar 2022

Interim (FY2022)

0.25———

23 Sep 2025

Final (FY2025)

1.00———

Credit Ratings

AgencyDateLong-termShort-termFacilities (INR Cr)Outlook

Acuité Ratings & Research

08 Sep 2026

ACUITE BBB- (assigned)

ACUITE A3 (assigned)

33.25 LT + 18.50 ST = 51.75

Stable

CARE Ratings

31 Mar 2026

CARE BB+ (reaffirmed)

CARE A4+ (reaffirmed)

17.75 CC + 12.00 LT/ST + 16.00 LC = 45.75

Stable

CARE Ratings

10 Mar 2025

CARE BB+

CARE A4+

—

Stable

CARE Ratings

11 Mar 2024 / 23 Feb 2024

CARE BB+ (downgraded from BBB-)

CARE A4+ (from A3)

—

Stable

CARE Ratings

06 Dec 2023

CARE BBB-

CARE A3

10 LT + 6 ST

Stable

CARE Ratings

20 Oct 2022

CARE BBB- (upgraded)

CARE A3

10 LT

Stable

CARE Ratings

2019–2021

CARE BB+

CARE A4+

10–17 LT

Stable

CARE Ratings

18 Oct 2018

CARE BB+ (downgraded)

CARE A4+

—

Stable

CARE Ratings

13 Apr 2017 / 02 Apr 2018

CARE BBB-

CARE A3

15 LT + 6 ST

Stable

Brickwork Ratings

25 Jul 2024; 16 May 2025

————

ICRA

07 Nov 2014

Suspended (non-cooperation)

———

Analyst Conclusions

Management guidance and consensus

Management does not issue guidance and holds no earnings calls; there is no sell-side consensus. The only forward-looking reference points are CARE's expectation (Mar-2026) of gross cash accruals of ~INR 9.5–10 Cr for FY2026 against negligible term-debt repayments, and its warning that any reduction in NPK subsidy allocation could affect FY2027 revenue and profitability. The Q1 FY2027 print (sales INR 28.92 Cr, –27% YoY; PAT INR 1.32 Cr, –69% YoY) suggests FY2027 is tracking below FY2026's record.

Bull case (3 arguments)

  1. Deep value on asset and earnings measures. At ~0.66x book and ~5.7x FY2026 earnings (≈6.3x TTM EV/EBITDA), the stock prices in a return to FY2024-style losses. If the company merely sustains FY2025-type profitability (~INR 5 Cr PAT), the equity is cheap relative to listed peers at 7–8x earnings.

  2. Structural tailwinds for SSP. Government preference for SSP as a cost-effective P-and-S source, recurring DAP supply tightness and higher NBS rates (Kharif 2025) underpinned record FY2026 revenue; PSU marketers (RCF to Jun 2027, IPL, HURL) want third-party SSP volume, giving a small producer with spare capacity a route to high utilisation.

  3. Credit and governance momentum. A second agency rated the company investment-grade (Acuité BBB-/A3 on INR 51.75 Cr) in September 2026, enhanced bank lines could relieve the working-capital bottleneck, the board now has four independents including two women, and the associate exit simplifies the reporting structure.

Bear case (3 arguments)

  1. Earnings already rolling over. Quarterly operating margin fell from 19.9% to 6.1% across FY2026 and Q1 FY2027 profit fell 69% YoY; with the subsidy budget trending down (INR 1.88 → 1.68 lakh Cr over FY2024–26), FY2026 may prove a cyclical peak.

  2. Competitive squeeze from integrated giants. Madhya Bharat (Dhule 330,000 MT SSP), Rama (Udaipur +65,000 MT; Dhule 216,000 MTPA greenfield) and Khaitan are adding acid-integrated capacity in Agro Phos's core markets; a non-integrated 160,000 MTPA producer has structurally higher costs and no pricing power.

  3. Liquidity and governance discount persists. CARE judges liquidity "stretched" with near-fully drawn lines and negative CFO in FY2024–25; the related-party sale of associate shares to the promoter, the stop-start independent-director re-appointment, the NSE results clarification and nil institutional ownership justify a persistent valuation discount.

Catalysts and monitorables (next 12 months)

MonitorableWhy it mattersExpected timing
Rabi 2026-27 and Kharif 2027 NBS rates for SSPPrimary driver of realisations and marginsOct 2026; Mar–Apr 2027
Q2 FY2027 resultsTest of whether H1 FY2027 decline is seasonal or structural~Nov 2026 (StockAnalysis estimates 12 Nov 2026)
Operating cash flow and debtor/inventory daysLiquidity stress indicator; CARE downgrade trigger if subsidy delays worsenHalf-yearly / FY2027 annual
RCF MoU volumes and renewal of IPL/HURL/Matix arrangementsVolume visibility for 160,000 MTPA capacityThrough Jun 2027
CARE annual review (due ~Mar 2027) vs Acuité BBB-Convergence or divergence of ratingsQ4 FY2027
Any new acquisition or capacity planOnly route to scale; previous attempt failedAd hoc
Dividend decision for FY2026/FY2027Signal of cash confidenceAGM Sep 2027
Related-party transactions and board stabilityGovernance discountOngoing
Monsoon 2027 forecast (IMD, Apr 2027)Kharif demandApr–Jun 2027

Concluding analyst verdict

Agro Phos (India) Limited is an honest but structurally limited business: a two-plant, 160,000 MTPA Single Super Phosphate converter in Madhya Pradesh whose profits are set in New Delhi (through NBS subsidy rates), in Casablanca and Amman (through rock-phosphate prices), and by the monsoon. FY2026 showed the business at its best — record revenue of INR 147.95 Cr, standalone net profit of roughly INR 8.2 Cr, a 12% ROE and an improved 93-day cash cycle — helped by restored SSP subsidy rates and DAP shortages. Yet the same year exposed the fragility: margins slid every quarter from Q1 to Q4, consolidated Q4 was loss-making, and Q1 FY2027 profit fell by more than two-thirds.

The balance sheet is not over-levered (net debt ≈ 1.7x EBITDA), but liquidity is tight and depends on bank lines and timely subsidy receipts. Strategically, the company has opted to be a capacity provider to national marketers (IPL, HURL, RCF) rather than a branded player, which secures volume but forfeits pricing power at the very moment integrated peers are adding hundreds of thousands of tonnes of acid-integrated SSP capacity in its backyard. The failed Bharat Phosphates acquisition removes the only visible growth lever, and governance — combined Chair/MD, promoter-sibling executives, a related-party share sale to the promoter and director-appointment churn — merits a discount.

At ~0.66x book and mid-single-digit earnings multiples, the market already discounts much of this; the stock trades near its 2016 IPO price. For investors, Agro Phos is a high-beta call on SSP subsidy policy rather than a compounding franchise. A constructive stance requires evidence of sustained positive operating cash flow, stable 10%+ operating margins through a full Kharif–Rabi cycle, and a credible capacity or integration plan. Absent these, the verdict is neutral with a negative bias: cheap, but cheap for identifiable reasons.


Source list (primary first): NSE corporate filings for AGROPHOS — results outcomes 14-Nov-2025 and 14-Feb-2026; integrated filing Q2 FY2026; Reg. 30 intimations dated 16-Jul-2025, 26-Feb-2026, 17-Mar-2026, 29-May-2026, 08-Sep-2026; record-date filing 06-Sep-2025; resignation filings 02-Sep-2024 and 29-May-2025; board outcome 17-Jan-2025; annual-report cover letters FY2023-24 and FY2025-26; AGM proceedings 2022. CARE Ratings press releases (13-Apr-2017; 02-Apr-2018; 18-Oct-2018; 03-Apr-2019; 23-Aug-2019; 29-Sep-2020; 17-Aug-2021; 20-Oct-2022; 06-Dec-2023; 31-Mar-2026). NSE Indices press release 06-Mar-2019. Business Standard/PTI, 16-Nov-2016. Aggregators reproducing filings: Screener.in; Arihant Capital/CMOTS; Anand Rathi; Kotak Neo; StockAnalysis; Simply Wall St; TipRanks; 5paisa; Chittorgarh; IIFL; DSIJ. Peer data: Rama Phosphates, Madhya Bharat Agro Products and Khaitan Chemicals & Fertilizers FY2026 results coverage (Capital Market, Free Press Journal, ScanX, StockAnalysis) and their NSE investor presentations.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameTitle / categoryTenure / key datesPrior roles & backgroundEducationAge

Raj Kumar Gupta (DIN 00244925)

Chairman & Managing Director; Promoter

Co-founder (2001); MD re-appointed for 3 years in Sept 2022 and again by Board on 17 Jan 2025

Over two decades in fertiliser industry (CARE); oversees overall business

B.Sc.

50 (as of Jan 2025 disclosure)

Vishnu Kant Gupta (DIN 05233476)

Whole-time Director; Chief Financial Officer (per vendor profile); Promoter

WTD re-appointed by Board 17 Jan 2025

~10 years in fertiliser industry; looks after production (CARE). Brother of Raj Kumar Gupta

——

Abhishek Kalekar

Non-Executive, Non-Independent Director

On board since at least 2022

Holds 150,000 shares (0.74%)

——

Mahesh Kumar Agarwal

Independent Director

On board since at least FY2024

———

Maya Vishwakarma

Independent Director; Chairperson of Audit and other committees from 26 Feb 2026

————

Chandresh Kumar Gupta (DIN 09042779)

Independent Director

First term ended 24 Jan 2026 (ceased); re-appointment proposal of 14 Feb 2026 withdrawn 26 Feb 2026; members approved re-appointment for five years from 30 Sep 2026

———

Sakina Dharwala

Independent Director

Appointed for five years from 11 Jul 2026; regularised at 30 Sep 2026 AGM

———

Reena Saluja

Company Secretary & Compliance Officer (KMP)

In role since at least 2024

ICSI member A55665

CS

—

“—” = not publicly disclosed.

Directors' Remuneration

AttributeStatus

Board size

7 (2 executive promoter directors, 1 non-executive non-independent, 4 independent) as of Oct 2026

Independence

4 of 7 independent (~57%) after Sakina Dharwala's appointment and Chandresh Kumar Gupta's re-appointment

Women directors

2 (Maya Vishwakarma, Sakina Dharwala)

Chair / CEO separation

Not separated — Raj Kumar Gupta is both Chairman and MD

Family relationships

Raj Kumar Gupta and Vishnu Kant Gupta are brothers (per Jan-2025 disclosure)

Audit Committee (post 26 Feb 2026)

Maya Vishwakarma (Chair, ID), Mahesh Kumar Agarwal (ID), Abhishek Kalekar (NED)

Nomination & Remuneration Committee (post 26 Feb 2026)

Maya Vishwakarma (Chair), Mahesh Kumar Agarwal, Abhishek Kalekar

Stakeholders' Relationship / CSR Committee

Raj Kumar Gupta (Chair), Vishnu Kant Gupta, Maya Vishwakarma (composition per 26 Feb 2026 filing)

Board & Management Changes

DateChangeContext

02 Sep 2024

Tushar Dave (ID) resigned

Cited pre-occupation and personal commitments

17 Jan 2025

MD and WTD re-appointed; EGM called

Routine re-appointment

29 May 2025

Shweta Bhamare (ID) resigned

Cited pre-occupation

14 Feb 2026

Board proposed second term for Chandresh Kumar Gupta as additional ID

Subject to shareholder approval

26 Feb 2026

Proposal withdrawn; Chandresh Kumar Gupta ceased (first term ended 24 Jan 2026); committees reconstituted

Reason for withdrawal not disclosed; note he had technically completed his term a month before the proposal

11 Jul 2026

Sakina Dharwala appointed ID

Board refresh

30 Sep 2026

Members approved Chandresh Kumar Gupta's re-appointment as ID for five years

Reversal of February withdrawal

Major Shareholders

Holder category% (Jun 2026)

Promoters & promoter group

54.27

Foreign institutional investors

0.00

Domestic institutional investors

0.00

Public / retail & others

45.73

Number of shareholders

18,650

Named holder

Shares

Raj Kumar Gupta (promoter)

4,708,895

Vishnu Kant Gupta (promoter)

2,337,985

Ramesh Suhane

1,795,050

Abhishek Kalekar (director)

150,000

Other promoter-group members

balance to 54.27%

Competitive Landscape

Key Competitors

#CompetitorListingPositioning vs Agro PhosFY2026 revenue (INR Cr)Notes
1

Khaitan Chemicals & Fertilizers

NSE/BSE

Largest or second-largest SSP producer; ~10% national SSP share; six units incl. Nimrani (MP) 400,000 MT; acid integration

≈ 1,003

FY2026 PAT INR 68.76 Cr; produced 440,271 MT SSP

2

Madhya Bharat Agro Products (Ostwal Group)

NSE/BSE

Sagar (MP) neighbour; SSP 240,000 MT + DAP/NPK 240,000 MT; Dhule (MH) SSP 330,000 MT; full acid/BRP integration

≈ 1,867

FY2026 PAT INR 150.18 Cr; SSP utilisation 98%

3

Rama Phosphates

NSE/BSE

SSP 914,000 MT → 979,000 MT after Udaipur expansion; greenfield Dhule SSP; soya segment

≈ 893

FY2026 PAT INR 52.71 Cr

4

Coromandel International

NSE/BSE

India's largest private phosphatic player with major SSP footprint

Not compiled (multi-thousand-crore scale)

—
5

Shri Tulsi Phosphate Ltd

Unlisted

Chhattisgarh; Agro Phos holds 19.51%

—

Former associate

6

Bharat Phosphates & Chemicals Pvt. Ltd.

Unlisted

Former acquisition target

——
7

Bohra Industries

Listed (SME)

Rajasthan SSP producer

—

Named as peer by Zerodha/Tickertape

8

Phosphate Company Ltd

Listed

West Bengal SSP producer

—

Named peer

9

Teesta Agro Industries

Listed

West Bengal SSP/fertiliser producer

—

Named peer

10

Basant Agro Tech (India)

Listed

Akola (MH) SSP and NPK mixtures

—

Named peer

11

Shiva Global Agro Industries

Listed

Nanded (MH) SSP/mixtures

—

Named peer

12

Indian Phosphate Ltd / Bharat Agri Fert & Realty / Saptak Chem & Business

Listed

Small SSP-related players

—

Named peers on broker pages

“—” = not publicly disclosed.

Peer Comparison FY2026

MetricAgro PhosMadhya Bharat AgroKhaitan ChemicalsRama Phosphates

Revenue (INR Cr)

147.951,866.981,003.1893.04

Revenue growth YoY (%)

23.476.339.120.1

Net profit (INR Cr)

8.17150.1868.7652.71

Net margin (%)

5.58.06.95.9

EBITDA / operating margin (%)

11.1—

10.6 (operating income / revenue)

8.8 (operating income / revenue)

SSP capacity (MTPA)

160,000570,000

~1100000 (sum of disclosed unit LACs, approx.)

914,000

Acid / backward integration

No

Yes (SA, PA, BRP)

Yes (SA)

Yes (SA)

Company Snapshot

$3.7M

Revenue

154

Employees

2001

Founded

Indore, India

Headquarters

SWOT Analysis

Strengths

  • Record revenue and restored profitability: FY2026 standalone revenue INR 147.95 Cr (+23%), PAT ≈ INR 8.17 Cr vs loss of INR 7.65 Cr in FY2024
  • Moderate leverage: Debt ≈ INR 30 Cr vs equity ≈ INR 70 Cr (D/E ≈ 0.43x, Screener); net debt/EBITDA ≈ 1.7x FY2026
  • Diversified institutional customer base: MoUs with IPL, HURL (125,350 MT), RCF (to Jun 2027), Matix (60,000 MTPA), MAIDC, BVFCL
  • Established distribution: 200+ dealers across six states (CARE, Mar-2026)
  • Experienced, committed promoters: Promoter group steady at 54.27% since listing; MD with 20+ years in fertilisers
  • Credit profile improving at second agency: Acuité BBB-; Stable / A3 assigned on INR 51.75 Cr (Sep 2026), above CARE's BB+
  • Low capital intensity: Net fixed assets ≈ INR 21 Cr supporting ≈ INR 148 Cr revenue (asset turnover ~0.95x on total assets; ~7x on fixed assets)

Weaknesses

  • Extreme product concentration: SSP ~99% of 9MFY2026 sales (CARE)
  • Stretched liquidity: Bank lines almost fully utilised for 12 months to Feb 2026; free cash INR 0.10 Cr at Mar-2025; negative CFO per CARE in FY2024 (–11.49 Cr) and FY2025 (–3.29 Cr)
  • Working-capital intensity: Inventory days 291 (FY2025), 177 (FY2026); operating cycle 135 days (CARE)
  • Volatile, low through-cycle returns: ROE –13.8% (FY2024) to 12.2% (FY2026); 3-year average ROE ≈ 3% (Screener)
  • No backward integration: Buys sulphuric acid locally and imports rock phosphate; peers own acid plants
  • Governance concentration: Chairman = MD; promoter brothers hold executive roles; related-party share sale to promoter (Dec 2025); ID churn (three exits/lapses in 18 months)
  • Weak exit rate: Quarterly OPM fell from 19.9% (Q1 FY26) to 6.1% (Q4 FY26); Q1 FY27 PAT –69% YoY

Opportunities

  • SSP substitution for DAP: DAP shortages in FY2026 shifted demand to SSP (peer commentary); government promotes SSP to balance NPK use
  • PSU marketing partnerships: RCF MoU (Mar 2026) adds a national distribution network through Jun 2027
  • Value-added SSP variants: Peers' Urea-SSP and fortified SSP launches show a market for differentiated products the company could replicate
  • Expanded bank limits: Acuité-rated facilities of INR 51.75 Cr vs CARE-rated INR 45.75 Cr could support higher throughput
  • Bolt-on acquisitions of distressed small SSP units: The (withdrawn) Bharat Phosphates deal at ≤ INR 3 Cr shows cheap capacity can be available
  • Organic / potash niches: PDM (K2O 14.5%) and PROM align with government push for organic and indigenous potash sources

Threats

  • Subsidy budget cuts: INR 1.88 → 1.71 → 1.68 lakh Cr (FY2024–26); CARE warns NPK allocation decline could hit FY2027
  • Peer capacity wave: Madhya Bharat Dhule 330,000 MT SSP; Rama +65,000 MT Udaipur and 216,000 MTPA Dhule greenfield; both in Agro Phos's core markets
  • Raw-material and FX volatility: Imported rock phosphate (Egypt, Jordan); no export hedge; forex loss INR 0.10 Cr FY2025
  • Monsoon failure: FY2024 losses partly attributed to inadequate rainfall (Directors' Report)
  • Subsidy payment delays: CARE negative sensitivity: delay in subsidy receipt further impacting liquidity
  • Equity-market de-rating and illiquidity: Price down ~45% in one year; nil institutional ownership; thin daily trading

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
29 May 2025Independent Director Shweta Bhamare resigns (pre-occupation)Second ID exit in nine months; independence thinned
05 Jun 2025Q4 FY2025 / FY2025 results: consolidated Q4 PAT INR 2.34 Cr; FY2025 standalone revenue INR 119.88 Cr, PAT INR 5.26 CrConfirms recovery from FY2024 loss
16 Jul 2025Board approves acquisition of Bharat Phosphates & Chemicals' business (≤ INR 3 Cr)First acquisition attempt; signals expansion intent
14 Aug 2025Q1 FY2026 results: standalone sales INR 39.80 Cr (+66% YoY), OPM 19.9%, PAT INR 4.29 Cr; consolidated PAT INR 4.37 Cr; appointments announcedBest quarter in company history on subsidy uplift and DAP shortage
06 Sep 2025Board recommends INR 1.00 final dividend for FY2025; record date 23 Sep 2025; AGM 30 Sep 2025Highest-ever payout
19 Sep 2025FY2024-25 annual report filed with NSEStatutory
23 Sep 2025Ex/record date for dividend—
30 Sep 202523rd AGM at Hotel Rasa Royal, IndoreDividend approved
c. 30 Oct 2025Dividend paid (~INR 2.03 Cr outflow)Cash outflow amid stretched liquidity
14 Nov 2025Q2 FY2026 results: standalone sales INR 40.08 Cr, PAT INR 2.01 Cr; consolidated PAT up ~384% YoYMargin compression begins (OPM 9.5%)
31 Dec 2025Board meeting: sale of 520,000 Shri Tulsi shares to promoter Raj Kumar Gupta for INR 76.44 lakh; director appointment itemAssociate exits consolidation; related-party transaction
09 Jan 2026Regulation 74(5) certificate for Dec-2025 quarterRoutine compliance
19 Jan 2026NSE seeks clarification on Q2 FY2026 results under Regulation 33–
24 Jan 2026Chandresh Kumar Gupta's first ID term endsGovernance gap until re-appointment
14 Feb 2026Q3 FY2026 results: standalone sales INR 35.84 Cr, PAT INR 0.85 Cr (–66% YoY); re-appointment proposal for Chandresh Kumar Gupta; committees reconstitutedProfit decline despite revenue growth
26 Feb 2026Re-appointment proposal withdrawn; Chandresh Kumar Gupta ceases; Maya Vishwakarma takes committee chairsGovernance churn
17 Mar 2026MoU with RCF for marketing/distribution of SSP (to 01 Jun 2027)New PSU channel
31 Mar 2026CARE reaffirms BB+; Stable / A4+; facilities rejigged to INR 45.75 Cr; analysis moved to standaloneCredit profile stable but sub-investment-grade
29 May 2026FY2026 audited results: record standalone revenue INR 147.95 Cr; standalone PAT ≈ INR 8.17 Cr; consolidated Q4 net loss ≈ INR 0.29 CrRecord year, weak exit rate
29 May 2026Bharat Phosphates acquisition withdrawnInorganic growth plan collapses
Jun 2026Shareholding unchanged at 54.27% promoter; retail holders down to 18,650No promoter buying despite price fall
11 Jul 2026Sakina Dharwala appointed Independent DirectorBoard refresh; second woman director
–Q1 FY2027 results: standalone sales INR 28.92 Cr (–27% YoY), PAT INR 1.32 Cr (–69% YoY), OPM 10.9%Sharp YoY decline against record base
07 Sep 2026FY2025-26 annual report and 24th AGM notice submitted to NSEStatutory
08 Sep 2026Acuité assigns BBB-; Stable (LT INR 33.25 Cr) / A3 (ST INR 18.50 Cr); total INR 51.75 CrInvestment-grade rating from a second agency, one notch above CARE's long-term rating
30 Sep 202624th AGM: Chandresh Kumar Gupta re-appointed ID for five years; Sakina Dharwala regularised; all agenda items passedIndependence restored
03 Oct 2026AGM voting results and scrutiniser report filedStatutory
09 Oct 2026Stock closes at INR 22.9 (market cap ≈ INR 46.4 Cr), near 52-week low; down ~45% in one yearMarket de-rating on earnings slowdown

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

2 charts
Income Statement: Revenue & Gross Profit: Revenue / net sales rose from INR 1,160.6 Mn in FY2022 to INR 1,479.5 Mn in FY2026.
Agro Phos (India) Limited — Income Statement: Revenue & Gross Profit
Series (INR Mn)FY2022FY2023FY2024FY2025FY2026
Revenue / net sales1,160.61,310.21,038.21,198.81,479.5
Gross profit365.3415.9230.8447—

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.